


Continuing foundational therapy in symptomatic heart failure: the key role of RAASi-based therapy

Shelley Zieroth, MD
Winnipeg, MB, Canada

Breaking barriers in guideline-based RAASi therapy: Solving issues with hyperkalemia



Continuing foundational therapy in symptomatic heart failure: the key role of RAASi-based therapy

Shelley Zieroth, MD, FRCPC, FCCS, FHFA (hon), FESC, FACC, FHFA

Professor of Medicine, Max Rady College of Medicine

University of Manitoba, Winnipeg, Canada

Past President Canadian Heart Failure Society

CCS HF Guidelines Co-Chair

President Federation of Medical Women of Canada

Disclosures:, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Eidos, Eli Lilly, GSK, Janssen, HLS Therapeutics, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Servier, Vifor, Canadian Medical and Surgical KT Group, CCRN, CCS, CHFS, Charite, EOCl, Liv, Medscape, Ology, PACE, PHRI, Radcliffe, Translational Medicine Academy, Vigour

Landmark trials have demonstrated that RAASi improves outcomes in patients with HFrEF

	Study	Key Inclusion Criteria	Follow-up (years)	Treatment Arms	Key Findings
ACEi	CONSENSUS¹ (N=253)	NYHA class IV	0.5 (mean)	Enalapril vs. placebo	Enalapril reduced mortality by 40% at 6 months and 31% at 12 months
	SOLVD² (N=2569)	NYHA class I-IV ^a , LVEF ≤35%	3.45 (mean)	Enalapril vs. placebo	Enalapril reduced mortality by 16% and the combination of mortality or hospitalization for worsening HF by 26%
	ATLAS³ (N=3164)	NYHA class II-IV; LVEF≤30%	3.8 (median)	Lisinopril low-dose (2.5-5 mg QD) vs. high-dose (32.5-35 mg QD)	High-dose lisinopril group had a non-significant reduction in mortality and CV mortality (8% and 10% reductions, respectively) and a significant reduction in the combination of mortality or hospitalization for any reason by 12% compared to low-dose group
MRA	RALES⁴ (N=1663)	NYHA class III or IV; LVEF ≤35%	2.0 (mean)	Spirolactone vs. placebo	Spirolactone reduced risk of all-cause mortality by 30% and hospitalization for worsening HF by 35%
	EMPHASIS-HF⁵ (N=2737)	NYHA class II; LVEF ≤35%	1.75 (median)	Eplerenone vs. placebo	Eplerenone reduced the composite of CV-related mortality or hospitalization for HF by 37% and all-cause mortality and CV mortality by 24% each
ARNI	PARADIGM-HF⁶ (N=8442)	NYHA class II-IV; LVEF≤40%	2.25 (median)	LCZ696 ^b vs. enalapril	LCZ696^b reduced risk of the combination of CV death or first hospitalization for worsening HF by 20% , all-cause mortality by 16%, and first hospitalization for worsening HF by 21%

^aApproximately 90% were NYHA class II-III; ^bLCZ69 is the combination of the neprilysin inhibitor sacubitril and the ARB valsartan.

RAASi therapy is recommended by clinical guidelines for the management of chronic HFrEF and should be titrated to maximum tolerated doses

2021 ESC GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF ACUTE AND CHRONIC HEART FAILURE

ESC guidelines key message for pharmacological treatments indicated in patients with (NYHA class II–IV) HFrEF (LVEF ≤40%): ACEi or ARNI, beta-blockers, MRA, and SGLT2 inhibitors are recommended as cornerstone therapies for patients with HFrEF

Recommendations	Class ^a	Level ^b
An ACEi is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.	I	A
A beta-blocker is recommended for patients with stable HFrEF to reduce the risk of HF hospitalization and death.	I	A
An MRA is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.	I	A
Dapagliflozin or empagliflozin are recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.	I	A
Sacubitril/valsartan is recommended as a replacement for an ACEi in patients with HFrEF to reduce the risk of HF hospitalization and death.	I	B


5.2.2 General principles of pharmacotherapy for heart failure with reduced ejection fraction

Modulation of the renin-angiotensin-aldosterone (RAAS) and sympathetic nervous systems with angiotensin-converting enzyme inhibitors (ACE-I) or an angiotensin receptor-neprilysin inhibitor (ARNI), beta-blockers, and mineralocorticoid receptor antagonists (MRA) has been shown to improve survival, reduce the risk of HF hospitalizations, and reduce symptoms in patients with HFrEF. These drugs serve as the foundations of pharmacotherapy for patients with HFrEF. The triad of an ACE-I/ARNI, a beta-blocker, and an MRA is recommended as cornerstone therapies for these patients, unless the drugs are contraindicated or not tolerated.^{103–105} They should be uptitrated to the doses used in the clinical trials (or to maximally tolerated doses if that is not possible). This guideline still recommends the use of ARNI as a replacement for ACE-I in suitable patients who remain symptomatic on ACE-I, beta-blocker, and MRA therapies; however, an ARNI may be considered as a first-line therapy instead of an ACE-I.^{106,107} The recommended doses of these drugs are given in Table 8. Angiotensin-receptor blockers (ARB) will

^aClass of recommendation; ^bLevel of evidence.

ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; ESC = European Society of Cardiology; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association; RAASi = renin-angiotensin-aldosterone system inhibitor; SGLT2 = sodium-glucose cotransporter 2.


GDMT for HFrEF



2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure - DOI: 10.1016/j.cardfail.2022.02.010




GDMT for HFmrEF



2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure - DOI: 10.1016/j.cardfail.2022.02.010






GDMT for HFpEF



2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure - DOI: 10.1016/j.cardfail.2022.02.010



Despite proven benefits of RAASi, many patients with HFrEF are not at target doses



^ahHF defined as 7 days prior to initiation of GDMT in Sweden and US, and 30 days prior to initiation of GDMT in UK.

ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; BIOSTAT-CHF = BIOlogy Study to Tailored Treatment in Chronic Heart Failure; CHAMP-HF = Change the Management of Patients with Heart Failure; GDMT = guideline-directed medical therapy; HFrEF = heart failure with reduced ejection fraction; hHF = hospitalization for heart failure; MRA = mineralocorticoid receptor antagonist; RAASi = renin-angiotensin-aldosterone system inhibitor; UK = United Kingdom; US = United States.


1. Greene SJ et al. *J Am Coll Cardiol.* 2019;73:2365-2383; 2. Savarese G et al. Online ahead of print. *Eur J Heart Fail.* 2021; 3. Voors AA et al. *Eur J Heart Fail.* 2016;18:716-726; 4. Kobayashi M et al. *Clin Cardiol.* 2021;44:780-788.



Hyperkalemia can be a barrier to target dose RAASi therapy in patients with heart failure

Multinational, prospective, observational study of 7401 ambulatory patients with chronic heart failure from 21 European and Mediterranean countries (ESC-HF Long-term Registry) from May 2011 to April 2013

Patients that had hyperkalemia as a reason for not being at target dose RAASi^a



Note: Hyperkalemia definition or diagnosis method was not provided in the study.


^aAdditional reasons for patients not being at target dose were: still in up-titration (33.7% for ACEis, 32.4% for ARBs, and 29.4% for MRAs), symptomatic hypotension (26.0% for ACEis and 25.9% for ARBs), worsening renal function (7.9% for ACEis, 10.1% for ARBs, and 9.7% for MRAs), cough (0.9% for ACEis), angioedema (0.2% for ACEis and 0.1% for ARBs), gynecomastia (2.0% for MRAs), and other/unknown (28.8% for ACEis, 29.3% for ARBs, and 46.9% for MRAs).

ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; ESC-HF = European Society of Cardiology-Heart Failure; MRA = mineralocorticoid receptor antagonist; RAASi = renin-angiotensin-aldosterone system inhibitor.

Patients with CKD and HF have recurrent hyperkalemia episodes, with successively shorter time between the episodes

Retrospective analysis using patient data from the CPRD database (medical records across the United Kingdom) linked to Hospital Episode Statistics between January 2008 and June 2018 in patients with a first diagnosis of CKD (n=297,702) or HF (n=84,210) and/or RAASi prescription (n=754,523)

Proportion of patients with recurrent hyperkalemia events




Note: Hyperkalemia defined as $K^+ \geq 5.0$ mmol/L. RAASi includes ACEi, ARB, MRA, and RI. Patients could fall into one or more overlapping cohorts based on their cardiorenal comorbidities and/or prescription record for RAASi and their assignment to a cohort was updated over time.

ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; CKD = chronic kidney disease; CPRD = Clinical Practice Research Datalink; HF = heart failure; HK = hyperkalemia; MRA = mineralocorticoid receptor antagonist; RAASi = renin-angiotensin-aldosterone system inhibitor; RI = renin inhibitor.

Tafesse E et al. *Int J Clin Pract.* 2021;75:e13941.

Optimizing RAASi therapy in patients with CKD and HF was associated with decreased mortality and MACE

An observational, longitudinal cohort study of RAASi-prescribed patients with new-onset CKD (n=100,572) or HF (n=13,113) using data from the CPRD and linked Hospital Episode Statistics between January 2006 and December 2015¹



Note: Non-fatal MACE defined as a composite of non-fatal arrhythmia, HF, myocardial infarction, and stroke. Poisson models were used to estimate adjusted IRRs and included covariates to control for patient characteristics and clinical histories. RAASi included specific ACEi, ARB, and MRA and the recommended dose was based on ESC 2016 guidelines² for the treatment of HF.¹

ACEi = angiotensin-converting enzyme inhibitor; Adj = adjusted; ARB = angiotensin-receptor blocker; CKD = chronic kidney disease; CPRD = Clinical Practice Research Datalink; ESC = European Society of Cardiology; HF = heart failure; IRR = incidence rate ratio; MACE = major adverse cardiac events; MRA = mineralocorticoid receptor antagonist; RAASi = renin-angiotensin-aldosterone system inhibitor.

1. Linde C et al. *J Am Heart Assoc.* 2019;8:e012655; 2. Ponikowski P et al. *Eur Heart J.* 2016;37:2129-2200.

Discontinuation or downtitration of RASi after an episode of hyperkalemia




Figure 3. Adjusted odds ratios (and 95% CIs) for dose modification of renin–angiotensin–aldosterone system inhibitors, stratified by serum potassium (K^+) threshold for CKD patients (**A**) and HF patients (**B**). An odds ratio of 1 (dotted line) indicates the odds of discontinuation or down-titration under the defined threshold.

In real world practice, discontinuation of RAASi therapy persists following a hyperkalemia event



76%

of patients were **not reintroduced to MRA therapy** during the subsequent year¹

Mean duration of RAASi discontinuation was:²

2.4 years

in patients with CKD



1.9 years


in patients with HF



Down-titration or discontinuation of RAASi therapy is associated with doubling of mortality across patient subtypes

Retrospective analysis of a US database of electronic health records (Humedica; N>200,000) of patients ≥5 years of age with various comorbidities, with at least 2 serum K⁺ readings, and with at least 1 outpatient RAASi prescription from 2007-2012

Mortality by prior RAASi dose




Note: RAASi includes ACEi, ARB, direct renin inhibitor, and select MRA.

ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; CKD = chronic kidney disease; HK = hyperkalemia; MRA = mineralocorticoid receptor antagonist; RAASi = renin-angiotensin-aldosterone system inhibitor; US = United States.

Epstein M et al. *Am J Manag Care*. 2015;21:S212–S220.


HFrEF GDMT: medications enabling tolerance of each other



SGLT2i and ARNI may have roles for enabling use of other life-prolonging HFrEF medications

These effects may be largely mediated via potassium handling

Optimal RAASi in the patient with HF:



ESC HF guidelines for the diagnosis and treatment of acute and chronic heart failure define RAASi therapy as ACEi, ARNI, and MRA.³

ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; CKD = chronic kidney disease; ESC = European Society of Cardiology; HF = heart failure; KDIGO = Kidney Disease: Improving Global Outcomes; MRA = mineralocorticoid receptor antagonist; RAASi = renin-angiotensin-aldosterone system inhibitor; RASi = renin-angiotensin system inhibitor.